Liver cancer

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a…

This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…

This study tests a combination of four drugs (gemcitabine, cisplatin, quemliclustat, and zimberelimab) as a first treatment for people with advanced biliary tract cancers, including bile duct cancer. The goal is to see if this mix can slow cancer growth and help people live longe…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis m…

This study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…

This early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the com…

This study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receiv…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This Phase 2 trial is testing a combination of paclitaxel polymer micelle and immunotherapy for people with advanced biliary tract cancer whose disease has progressed after standard first-line treatment. The study aims to see if this new drug combo can shrink tumors and control t…

This trial is testing whether a combination of chemotherapy, immunotherapy, and a targeted therapy can help people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be removed with surgery. Participants receive a regimen of two chemotherapy drugs (oxa…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests a daily pill called ivosidenib in 220 adults with advanced bile duct cancer that has a specific IDH1 gene mutation and has not responded to prior treatment. The goal is to confirm the drug's safety and effectiveness. Participants take the tablet once daily in 28-…

This trial is testing whether combining two types of radiation therapy can safely treat liver cancer that cannot be removed with surgery. The approach uses Y-90 microspheres delivered directly to the liver, followed by targeted external radiation (SBRT). The study also uses PET-C…

This trial is testing whether giving a combination of drugs before surgery can reduce the risk of liver cancer returning in patients with a single, early-stage tumor that has a high chance of recurrence. Participants will receive either chemotherapy directly into the liver or a t…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive t…

This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…

This trial tests whether giving a personalized dendritic cell vaccine before a standard liver-directed therapy (TACE) can improve outcomes for people with advanced liver cancer that has not responded to other treatments. The vaccine is made from the patient's own immune cells and…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This phase 2 trial is testing whether adding either ramucirumab (a blood-vessel blocker) or merestinib (a cell-signal blocker) to standard chemotherapy (cisplatin + gemcitabine) can help people with advanced or metastatic biliary tract cancer live longer without their disease wor…

This study tests a combination of the drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) in 16 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This phase 2 trial tests whether a powerful mix of liver-directed chemotherapy, a targeted drug (lenvatinib), and an immunotherapy (cadonilimab) can shrink liver cancers that were too large or widespread to remove. The goal is to convert these inoperable tumors into ones that can…

This study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…

This study tests an experimental treatment called GKL-006, made from a person's own immune cells (iNKT cells), for liver cancer that cannot be surgically removed. Participants receive GKL-006 injections along with a standard procedure that blocks the tumor's blood supply (TACE). …

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This phase 2 trial tests an experimental drug called SHR-A1811 in people with advanced biliary tract cancer that has HER2 expression or amplification and has stopped responding to earlier treatments. The drug is an antibody-drug conjugate designed to deliver a chemotherapy-like p…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This Phase 3 trial tests an oral drug called tinengotinib against standard treatments chosen by the doctor for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic alteration (FGFR) and has stopped responding to chemotherapy and an FGFR inhibitor…

This study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…

This Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…

This phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …

This phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…

This study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a standard two-drug combination (lenvatinib and a PD-1 inhibitor) helps people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will receive either the …

This phase II trial tests a combination of two drugs (anlotinib and cadonilimab) plus a special type of radiation (PULSAR) in 26 people with advanced bile duct cancer that has worsened after standard treatment. The goal is to see if this triple therapy can shrink tumors and contr…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…

This phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is…

This study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…

This study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…

This study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal i…

This phase 2 trial is testing whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease has progressed while on sorafenib alone. The study enrolls 30 adults with confirmed liver cancer and Child-Pugh A cirrhosis or no cirrhosis. Researchers …

This phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…

This early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…

This early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This study tests a new oil called T-ACE Oil, mixed with a chemotherapy drug, for people with liver cancer that cannot be removed by surgery. The oil is injected directly into the liver's blood vessels to block them and deliver chemo to the tumor. The trial aims to see if it is sa…

This study tests a special electrode for radiofrequency ablation in people with small liver cancers (3 cm or less). The electrode monitors temperature and can adjust its tip to match tumor shape, aiming to destroy the tumor while protecting nearby organs. Researchers will track w…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or canno…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

This study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…

This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…

This study tests a new, stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) with he…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…

This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…

This phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before an…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…

This phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Par…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This phase 2 trial tests a combination of immunotherapy (camrelizumab), a targeted therapy (apatinib), and chemotherapy (gemcitabine and oxaliplatin) given before and after surgery for 30 people with advanced biliary tract cancer. The goal is to see if this approach can shrink tu…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This early-stage trial is testing a combination of two drugs—cadonilimab and regorafenib—in 30 adults with advanced liver cancer that has worsened after at least one prior therapy. The goal is to see if the combo can shrink tumors or slow the disease, while also checking for side…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study tests a combination of two drugs (toripalimab and bevacizumab) alongside three types of artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the ca…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control…

This study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrat…

This study tests whether the drug everolimus can lower the risk of liver cancer coming back after a liver transplant in patients with high-risk hepatocellular carcinoma. About 336 adults who have just received a transplant will be randomly assigned to take everolimus plus tacroli…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This pilot trial is testing whether adding stereotactic body radiation therapy (SBRT) to the standard transarterial chemoembolization (TACE) can better control liver cancer in patients waiting for a liver transplant. About 40 patients will be enrolled to see if the combination im…

This Phase 2 study is testing a combination of three drugs—nanoliposomal irinotecan, fluorouracil, and leucovorin—in 48 adults with advanced biliary tract cancer that has progressed after initial chemotherapy. The main goal is to see if the treatment can stop the cancer from grow…

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination …

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This study tests whether adding a liver-directed chemotherapy infusion to a two-drug immunotherapy regimen can help people with advanced liver cancer that has spread to the main vein of the liver. About 214 participants will be randomly assigned to receive either the triple thera…

This Phase 3 trial tests whether a single high dose of the steroid methylprednisolone, given during surgery, can reduce major complications in 1200 people undergoing elective surgery for digestive cancers. The goal is to calm harmful inflammation that can worsen outcomes. Results…

This Phase 3 trial is testing whether a new immunotherapy drug called AK112, when combined with standard chemotherapy, works better than another immunotherapy (durvalumab) plus the same chemo for people with advanced bile duct cancer. The study includes 682 participants who have …

This early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays …

This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…

This study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…

This study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can…

This study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …

This study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…

This study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find …

This pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…

This phase 2 trial tests whether a vaccine made from a patient's own dendritic cells — immune cells trained to recognize liver cancer — can prevent the cancer from returning after surgical removal of the tumor. About 74 adults with a high risk of recurrence will receive the vacci…

This study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors …

This study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …

This study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…

This study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…

This study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…

This study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…

This study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …

This study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This trial compares two ways to control pain after open liver surgery: an epidural pump that delivers pain medicine near the spine, versus a standard IV pump. About 230 adults having elective open liver resection will be randomly assigned to one method. The goal is to see which a…

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level…

This study tests whether a virtual group writing program can improve quality of life for young adults who survived cancer. Thirty survivors aged 18-39, diagnosed 1-5 years ago, will write about their cancer experiences in a group setting. The goal is to see if this simple, access…

This study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…

This trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study tests whether a smartphone app called MAELA® can help people recover better after surgery for digestive cancers. About 555 adults will use the app to report symptoms for 90 days after surgery, while doctors monitor alerts. The goal is to see if the app reduces serious …

This study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …

This study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…

This study tests whether a 4-week program of exercise, nutrition advice, and stress management before major gastrointestinal cancer surgery can reduce serious complications within 30 days after the operation. About 400 adult patients scheduled for elective GI cancer surgery will …

This study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…

This study compares two minimally invasive procedures to drain blocked bile ducts in patients with incurable cancer. One method drains the bile duct into the intestine, the other drains the gallbladder into the stomach. The goal is to see which approach causes fewer complications…

This study compares two procedures to relieve bile duct blockage caused by cancer. About 120 patients with pancreatic or bile duct cancer will be randomly assigned to get either a newer ultrasound-guided drainage or the standard ERCP procedure. The goal is to see which method has…

This study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…

This study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…

This early-phase study looks at whether Emotional Freedom Techniques (EFT) — a practice that combines tapping on acupressure points with counseling — can reduce anxiety, depression, pain, and insomnia in people with cholangiocarcinoma, a rare and aggressive bile duct cancer. Four…

This study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …

This study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…

This study tests a nurse-led program that starts at least a week before liver cancer surgery. It includes exercise, nutrition advice, mental support, and help quitting smoking or drinking. The goal is to see if this program helps patients stay stronger, feel less anxious, and hav…

This study tests whether virtual yoga classes can help cancer survivors who have trouble sleeping. About 42 survivors will either take 8 virtual yoga sessions over 4 weeks or continue their usual care. Researchers will measure changes in insomnia and sleep quality to see if the o…

This study tests a group program called the Relaxation Response Resiliency Program (3RP-AYA) for adolescents and young adults who finished cancer treatment in the last 5 years. The program uses mind-body techniques like imagery, relaxation, and yoga to reduce stress and build res…

This study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …

This study compares a new bipolar knife to a standard monopolar knife for removing colon polyps using a procedure called endoscopic submucosal dissection (ESD). About 80 adults with colon growths will be randomly assigned to one knife. Researchers will measure how fast the proced…

This study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study tests an electronic symptom management system called Nurse AMIE in 344 people with stage 3 or 4 cancer living in rural areas. The goal is to see if using the system helps them live longer and improves their quality of life. Participants use the system to report symptom…

This study aimed to see if a special needle treatment (ultrasound-guided neuromodulation) could reduce front knee pain in cancer patients better than standard painkillers. It was planned for adults aged 18-65 with knee pain related to cancer. However, the study was withdrawn befo…

This trial was designed to see if nerve stimulation techniques could reduce lower limb pain in cancer patients better than medication. It was withdrawn before enrolling any participants, so no results are available. The study would have compared ultrasound-guided percutaneous neu…

This study compares two brief online educational programs for young women (ages 19-49) who have finished cancer treatment and are dealing with sexual health issues. Participants join video sessions and report changes in sexual function and emotional well-being. The goal is to fin…

This study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…

This study tests a modified way of giving two chemotherapy drugs (capecitabine and oxaliplatin) to people with gastrointestinal cancers. The goal is to see if the new schedule causes fewer side effects, like nerve damage and low blood counts, compared to standard treatments. Abou…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study looks at whether a supervised exercise program in community settings can improve quality of life and reduce fatigue in adults with cancer. 492 participants, including survivors and those on active treatment, will take part in group exercise sessions. Researchers will t…

This study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…

This trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…

This study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at whether a dye called iohexol can help doctors better calculate the dose of the chemotherapy drug carboplatin for cancer patients. The goal is to make sure patients get the right amount of drug to fight their cancer while reducing side effects. About 318 men wi…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study looks at whether a mobile health program combined with social media can help teens and young adults who survived childhood cancer become more physically active. About 387 participants will either use the program plus a fitness tracker or just the tracker alone. The goa…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks back at the records of about 800 adults who had minimally invasive liver surgery (laparoscopic, robotic, or hybrid) at specialized Italian centers. The goal is to see how the choice of surgical tools and techniques for cutting liver tissue relates to the risk of …

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…

This study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…

This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…

This large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…

This study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug d…

This study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The g…

This study follows people with liver cancer who are scheduled for surgery, measuring tiny molecules called microRNAs in their blood before and after the operation. The goal is to find patterns that could signal whether the cancer has come back. Researchers will also look at gut b…

This study follows 2,002 people at high risk for liver cancer to find better ways to detect it early. Researchers are testing a panel of blood-based miRNA markers, gut microbiome changes, and MRI-based AI algorithms to predict who develops the disease. The goal is to improve on c…

This study compares two different information sheets given to advanced cancer patients and their caregivers before a doctor visit. One sheet has sample questions to ask, the other has general information. The goal is to see which one helps patients and caregivers communicate bett…

This study looks at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to gather information on experiences like exposure, isolation, and financial disruptions. The goal is to underst…

This study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…

This study looks back at 371 adults who received a living donor liver transplant for hepatocellular carcinoma (a type of liver cancer) to see whether receiving a liver from a donor with an incompatible blood type affects long-term survival or cancer recurrence. Researchers compar…

This study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…

This trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …

This study tracks quality of life in 118 people with cancer who have a blocked bile duct and undergo a drainage procedure. Participants fill out a questionnaire before the procedure and again at 4 weeks, 12 weeks, and 6 months after. The goal is to see whether a drainage catheter…

This study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…

This study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already …

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…

This study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed …

This study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…

This study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…

This study reviews medical records of 126 adults treated for liver or bile duct diseases (both non-cancerous and cancerous) since 2005. The goal is to see how well different treatments work and to find ways to improve survival, control symptoms, and lower risks. No new treatments…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gi…

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…

This study compares two surgical techniques—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called nonpancreatic periampullary adenocarcinoma. Researchers will track how long patients stay in the hospital after surgery, as well as survival rat…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …

This study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help deci…

This study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…

This study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…

This study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.

This study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study reviews medical records of 10,000 people with lung or gastrointestinal cancers to see if PET scans can identify tumors that cause cachexia—a condition of severe weight loss and weakness. Researchers will compare PET scan results with patients' weight and performance st…

This study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…

This study checks if a computer model called LIRIC can accurately predict who will develop liver cancer using electronic health records. Researchers will track 6 million adults aged 40 and older without a history of liver cancer to see how well the model works. The goal is to imp…

This study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…

This study looks at whether older adults with cancer can use computer surveys (like on a tablet or computer) to answer health questions. Researchers want to see if these digital tools are easy to use, reliable, and give the same results as paper surveys. About 100 people aged 65 …

This study aims to create a more accurate way to measure depression in older adults who have or had cancer. Researchers will interview patients and test a new questionnaire designed specifically for this group. The goal is to improve how doctors identify and treat depression in o…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study tests whether a geriatric assessment tool—looking at thinking, memory, daily activities, and emotional well-being—can predict serious side effects from chemotherapy in older adults with cancer. Over 1,000 patients completed questionnaires and cognitive tests before and…

This study looks at how people with chronic cancer pain take their long-acting opioid medications. The goal is to learn from their experiences and develop a better way to manage cancer pain. About 150 adults who are prescribed long-acting opioids for cancer pain will participate.…

This study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …

This study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…

This study tests a communication method to help cancer patients and the general public learn about clinical trials and make informed decisions about joining. About 581 participants will receive information to increase their awareness and positive attitudes toward trials. The goal…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study is a registry that follows 1,000 adults with liver cancer who receive a liver transplant. Researchers will track how long patients live without their cancer coming back and overall survival. The goal is to learn more about outcomes and what predicts recurrence, not to …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study tests whether an automatic reminder in the electronic health record can increase the number of cirrhosis patients who get screened for liver cancer (hepatocellular carcinoma). The reminder prompts doctors to order a liver ultrasound when they see a patient with cirrhos…

This study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …

This study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …

This study collects information from 100 adults with breast, lung, gastrointestinal cancer, or multiple myeloma. Participants fill out weekly online surveys about their symptoms and treatment experiences for at least 12 weeks. The goal is to learn how symptoms change over time an…

This study looks at why some adults with advanced cancer are afraid to take opioids for pain, even when prescribed. Researchers will survey 50 patients to measure how fear, anxiety, and depression affect pain levels and medication use. The goal is to identify barriers so that pai…

This study surveys over 1,200 cancer patients who previously took part in behavioral trials to learn how the COVID-19 pandemic impacted their quality of life, mental health, and daily routines. Participants fill out questionnaires about stress, sleep, diet, exercise, and social s…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…

This pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…

This study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…

This study is a registry that collects information from patients who have a procedure called percutaneous cholangiopancreatoscopy (PCPS). During PCPS, doctors use a tiny camera to see inside the bile ducts and remove stones or take tissue samples. The goal is to learn how well th…

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…